Lambert, Mélanie <br/><br/>
Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension.  [electronic resource] 

 -  Cardiovascular research  05 2018 
 - 880-893 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1755-3245 
<br/><br/><label>Standard No.: </label>10.1093/cvr/cvy016  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Action Potentials<br/>Adolescent<br/>Adult<br/>Animals<br/>Case-Control Studies<br/>Disease Models, Animal<br/>Down-Regulation<br/>Female<br/>Humans<br/>Hypertension, Pulmonary--complications<br/>Hypertrophy, Right Ventricular--etiology<br/>Male<br/>Middle Aged<br/>Myocytes, Cardiac--drug effects<br/>Nerve Tissue Proteins--antagonists & inhibitors<br/>Potassium Channel Blockers--pharmacology<br/>Potassium Channels, Tandem Pore Domain--antagonists & inhibitors<br/>Rats<br/>Signal Transduction<br/>Sulfonamides--pharmacology<br/>Time Factors<br/>Ventricular Dysfunction, Right--etiology<br/>Ventricular Function, Right--drug effects<br/>Ventricular Remodeling--drug effects<br/>ortho-Aminobenzoates--pharmacology